Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Validation of a Dutch version of the Neurological Fatigue Index (NFI-MS) for patients with multiple sclerosis in the Netherlands.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
Brain Hemodynamic Changes Associated with Chronic Cerebrospinal Venous Insufficiency Are Not Specific to Multiple Sclerosis and Do Not Increase Its Severity.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Inhibition of glycerophosphate-dependent H2O2 generation in brown fat mitochondria by idebenone.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.

Pages